{"title":"民主党接管众议院引发药品价格立法谈判:但由于患者和行业的反对，强有力的立法不太可能。","authors":"Stephen Barlas","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>HHS has proposed regulations to attack high drug prices, a priority for the current administration. Both parties have spoken out against the drug companies but the change in control of the House is no guarantee of pricing legislation moving forward. And if drug manufacturers, PBMs, and others are adamant about tackling drug prices, why do they oppose the best cost-cutting proposals?</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 4","pages":"180-200"},"PeriodicalIF":0.0000,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428499/pdf/ptj4404180.pdf","citationCount":"0","resultStr":"{\"title\":\"Democratic Takeover of House Sparks Drug-Price Legislation Talks: But Strong Legislation Unlikely Given Patient and Industry Opposition.\",\"authors\":\"Stephen Barlas\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>HHS has proposed regulations to attack high drug prices, a priority for the current administration. Both parties have spoken out against the drug companies but the change in control of the House is no guarantee of pricing legislation moving forward. And if drug manufacturers, PBMs, and others are adamant about tackling drug prices, why do they oppose the best cost-cutting proposals?</p>\",\"PeriodicalId\":38773,\"journal\":{\"name\":\"P and T\",\"volume\":\"44 4\",\"pages\":\"180-200\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6428499/pdf/ptj4404180.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"P and T\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"P and T","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}
Democratic Takeover of House Sparks Drug-Price Legislation Talks: But Strong Legislation Unlikely Given Patient and Industry Opposition.
HHS has proposed regulations to attack high drug prices, a priority for the current administration. Both parties have spoken out against the drug companies but the change in control of the House is no guarantee of pricing legislation moving forward. And if drug manufacturers, PBMs, and others are adamant about tackling drug prices, why do they oppose the best cost-cutting proposals?
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
